The use of black box algorithms in medicine has raised scholarly concerns due to their opaqueness and lack of trustworthiness. Concerns about potential bias, accountability and responsibility, patient ...
This is meant to be used with the crosshair overlay module for https://recursiontracker.com/ Finding the crosshair path and where to put it is in the Installation ...
Abstract: In this article, we present a recursive least squares (RLS) and adaptive Kalman filter (AKF)-based state and parameter estimation (SE and PE) for series arc fault (SAF) detection and ...
Abstract: In this article, we propose a computationally and communicationally efficient approach for decision-making in nonequilibrium stochastic games. In particular, due to the inherent complexity ...
Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...
Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback